FIELD: medicine; oncology.
SUBSTANCE: present group of inventions refers to treatment of cancer, refractory to trastuzumab emtansine (T-DM1). That is ensured by administering an effective amount of a duocarmycin-containing conjugate of formula (I)
.
EFFECT: it provides effective treatment by overcoming refractoriness to anticancer therapy in patients with HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer, especially breast cancer.
13 cl, 1 tbl, 1 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WITH DUOCARMICIN USED FOR TREATING ENDOMETRIAL CANCER | 2015 |
|
RU2686085C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING | 2009 |
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS | 2018 |
|
RU2781195C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE | 2013 |
|
RU2671489C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
